Lexaria enters $5.925M at-the-market equity distribution agreement with Maxim Group

Lexaria Bioscience Corp.

Aggregate offering price of up to $5,925,000 of common stock through Maxim Group as distribution agent.
Sales made at market pursuant to existing S-3 registration statement (effective Feb. 4, 2022).
Commission of 3% of gross proceeds paid to Maxim; Company also reimburses certain expenses.
Company not obligated to sell any shares; termination on sale completion or agreement termination.
Agreement contains customary representations, warranties, and indemnification provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.